, /PRNewswire/ -- MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, celebrates the publication of a groundbreaking study in the prestigious Burns Journal. Titled the study demonstrates the unparalleled potential of MolecuLight's innovative technology in predicting skin graft integration outcomes for burn patients.
This study investigated the predictive capabilities of MolecuLight's fluorescence imaging in assessing bacterial presence that could be linked to skin graft failure within burn wounds. The results revealed significant correlations between the presence or absence of bacterial presence (higher than 10 CFU/gr tissue) on the graft bed immediately before skin grafting, and graft failure or success. Key findings from the study include: "These compelling results underscore the transformative impact of MolecuLight in burn wound management – yet another area of wound care where our technology drives change," said Anil Amlani, CEO at MolecuLight Inc.
"By providing clinicians with real-time, objective data on bacterial presence, MolecuLight's fluorescence imaging technology empowers them to make more informed decisions, ultimately leading to improved patient outcomes. The results of this study suggest that eliminating fluorescence signals at the graft site has the potential to enhance graft-take." Dr.
, lead author of the study remarks, "Our recent publication involving fluorescence imaging and i.